Compare SCD & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | ORGO |
|---|---|---|
| Founded | 2003 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.2M | 299.8M |
| IPO Year | N/A | 2016 |
| Metric | SCD | ORGO |
|---|---|---|
| Price | $15.45 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 45.5K | ★ 862.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $13.79 | $2.04 |
| 52 Week High | $16.18 | $7.08 |
| Indicator | SCD | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 43.41 |
| Support Level | $14.96 | $2.24 |
| Resistance Level | $15.48 | $2.67 |
| Average True Range (ATR) | 0.28 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 54.70 | 27.67 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.